Drug-resistant tuberculosis in Shanghai, China, 2000-2006: Prevalence, trends and risk factors

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 2, 2009, Pages 253-259

  Shen, X ^a,b   DeRiemer, K ^c   Yuan, Z An ^a   Shen, M ^a   Xia, Z ^a   Gui, X ^a   Wang, L ^a   Gao, Qian ^b   Mei, Jian ^a  

^a SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug resistance; Epidemiology; MDR TB; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHINA; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIGRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SHORT COURSE THERAPY; TUBERCULOSIS CONTROL; URBAN AREA;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSIENTS AND MIGRANTS; TUBERCULOSIS, MULTIDRUG-RESISTANT; URBAN HEALTH; YOUNG ADULT;

EID: 59549089746     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for anti-tuberculosis drug resistance, 1994-1997. World Health Organization- International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
2. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
3. Aziz M A, Wright A, Laszlo A, et al. Epidemiology of anti-tuberculosis drug resistance (The Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154.
4. Wright A, Bai G, Barrera L, et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR 2006; 55: 301-305.
5. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
6. Zignol M, Hosseini M S, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194: 479-485.
7. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
8. Espinal M A, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
9. Moore M, Onorato I M, McCray E, Castro K G. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-837.
10. Granich R M, Oh P, Lewis B, Porco T C, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293: 2732-2739.
11. Faustini A, Hall A J, Perucci C A. Risk factors for multidrug-resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163.
12. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002; 57: 477-482.
13. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of muiti-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
14. Shanghai Municipal Statistics Bureau. Report on 1% sample survey of population, Shanghai, 2005. Shanghai, China: Shanghai Municipal Statistics Bureau, 2005. http://www.stats-sh.gov.cn/rkdc/ynews/bsdt/bsdt/2006-9-21/ 20069211434447634.htm Accessed December 2007.
15. Zhang S, Yuan Z, Mei J, Shen M, Shen X. The effectiveness of the new TB control network in Shanghai. J Chinese Anti-tuberculosis Assoc 2007; 29: 74-77.
16. Li X, Zhang Y, Shen X, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis 2007; 195: 864-869.
17. Shen G, Xue Z, Shen X, et al. Recurrent tuberculosis and exogenous re-infection, Shanghai, China. Emerg Infect Dis 2006; 12: 1776-1778.
18. Barnes P F, Yang Z, Preston-Martin S, et al. Patterns of tuberculosis transmission in Central Los Angeles. JAMA 1997; 278: 1159-1163.
19. Alland D, Kalkut G E, Moss A R, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
20. Small P M, Hopewell P C, Singh S P, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
21. Telles M A, Ferrazoli L, Waldman E A, et al. A population-based study of drug resistance and transmission of tuberculosis in an urban community. Int J Tuberc Lung Dis 2005; 9: 970-976.
22. Munsiff S S, Li J, Cook S V, et al. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect Dis 2006; 42: 1702-1710.
23. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
24. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.
25. Yew W. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy 1999; 45 (Suppl 2): 26-33.
26. Zhang L X, Tu D H, Enarson D A. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000; 4: 904-910.
27. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2006: CD003343.